Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair.

@article{Fischer2007ChemotherapeuticSC,
  title={Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair.},
  author={Joshua L. Fischer and Elaine M Mihelc and Karen E. Pollok and Martin L. Smith},
  journal={Molecular cancer therapeutics},
  year={2007},
  volume={6 1},
  pages={355-61}
}
Selenium in various chemical forms has been the subject of cancer chemoprevention trials, but, more recently, selenium has been used in combination with DNA-damaging chemotherapeutics. Specifically, selenium protected tissues from dose-limiting toxicity and, in fact, allowed delivery of higher chemotherapeutic doses. At the same time, selenium did not protect cancer cells. Therefore, we seek to define the genetic basis for the observed selectivity of selenium in combination chemotherapeutics… CONTINUE READING
30 Citations
34 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

A Phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (CPT-11) in patients with advanced solid tumors

  • MG Fakih, L Pendyala, PJ Creaven, P Smith, ME Ross, Y. Rustum
  • Proc Am Assoc Cancer Res
  • 2006
2 Excerpts

Chemotherapeutic selectivity conferred by selenium: a role for p53dependent DNA repair

  • JL Fischer, S Cao, FA Durrani, M Fakih, YM Rustum, ML. Smith
  • Proc Am Assoc Cancer Res
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…